文献速递呼吸衰竭与机械通气消化、代谢与肾脏急症

FLHASc评分在急诊科咯血患者风险分层中的验证与实施

Validation and implementation of the FLHASc score for risk stratification of patients with hemoptysis in the emergency department.
PubMed 文献 · Am J Emerg Med · 2026-03-24
一句话结论多中心前瞻性队列显示,简化FLHASc2联合胸片可将近半数急诊咯血患者识别为低危(事件率0.87%,阴性预测值99.1%),但作者认为需前瞻性管理试验确认其临床影响。

该研究基于POPEIHE多中心前瞻性队列(NCT06067997),纳入9家意大利急诊科连续就诊的546例成人咯血患者,主要终点为院内死亡、需通气支持、ICU入住、输血或有创止血操作的复合终点。原始FLHASc区分度中等(AUC 0.71,95%CI 0.65-0.76),校准欠佳;新推导的FLHASc2在推导队列AUC 0.79(95%CI 0.73-0.87)、验证队列AUC 0.81(95%CI 0.73-0.88),Brier评分均<0.10。简化版sFLHASc2每变量计1分,准确度相当(AUC 0.80,95%CI 0.72-0.87),识别47.8%患者为低危(事件率2.7%);联合胸片阴性时该亚组事件率降至0.87%,阴性预测值99.1%(95%CI 96.5-100%)。作者结论认为sFLHASc2联合胸片可能使近半数病例安全离院,但需前瞻性管理试验确认。

要点

  • sFLHASc2每变量计1分,将47.8%的急诊咯血患者归为低危,该组短期不良事件率为2.7%。
  • sFLHASc2低危且胸片阴性者事件率降至0.87%,阴性预测值99.1%(95%CI 96.5-100%)。
  • 原始FLHASc区分度中等(AUC 0.71,95%CI 0.65-0.76)且校准欠佳,不如新模型FLHASc2。
  • FLHASc2验证队列AUC 0.81(95%CI 0.73-0.88),推导队列AUC 0.79(95%CI 0.73-0.87),Brier评分均<0.10。
  • 作者认为sFLHASc2联合胸片可能使近半数咯血病例安全离院,但需前瞻性管理试验确认其临床影响。

适用人群与场景

  • 9家意大利急诊科连续就诊的成人咯血患者,共546例(POPEIHE研究,NCT06067997)。

诊断标准与关键阈值

  • 简化FLHASc2(sFLHASc2)每个变量计1分,用于识别低危患者。
  • sFLHASc2低危定义为评分对应的低危组,该组占47.8%,短期不良事件率2.7%。
  • sFLHASc2低危联合胸片阴性者事件率0.87%,阴性预测值99.1%(95%CI 96.5-100%)。

研究设计与关键结果

  • 研究类型为多中心前瞻性队列(POPEIHE,NCT06067997),纳入9家意大利急诊科546例连续成人咯血患者。
  • 主要终点为院内死亡、需通气支持、ICU入住、输血或有创止血操作的复合终点。
  • 原始FLHASc区分度中等(AUC 0.71,95%CI 0.65-0.76),校准欠佳。
  • FLHASc2在随机推导队列(n=321)AUC 0.79(95%CI 0.73-0.87),在验证队列(n=225)AUC 0.81(95%CI 0.73-0.88),两队列Brier评分均<0.10。
  • 简化版sFLHASc2每变量计1分,准确度与FLHASc2相当(AUC 0.80,95%CI 0.72-0.87)。
  • sFLHASc2识别47.8%患者为低危,该组事件率2.7%;联合胸片阴性时事件率降至0.87%,阴性预测值99.1%(95%CI 96.5-100%)。

证据类型、等级与局限

  • 证据类型:多中心前瞻性队列研究(POPEIHE,NCT06067997)。
  • 作者结论:FLHASc2及其简化版是识别咯血患者短期不良结局低危的准确预后工具;sFLHASc2联合胸片可能使近半数病例安全离院。
  • 局限:作者指出需前瞻性管理试验确认其临床影响。

对床旁实践的改变

  • 作者认为sFLHASc2联合胸片可用于识别低危咯血患者,可能使近半数病例安全离院,但该做法尚需前瞻性管理试验确认。
  • 原始FLHASc区分度中等且校准欠佳,床旁使用新模型FLHASc2或简化版sFLHASc2可能更准确。

指南或共识出处

  • POPEIHE研究(NCT06067997),发表于Am J Emerg Med。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「处置流程与药物剂量」「红旗征与不能漏的情况」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

BACKGROUND: Hemoptysis is a potentially life-threatening symptom that often prompts emergency department (ED) evaluation and hospitalization. Reliable prognostic tools to guide clinical decision-making and optimize resource use are currently lacking.

OBJECTIVE: To prospectively validate the Florence Hemoptysis Assessment Score (FLHASc) in patients presenting with hemoptysis to the ED, and to eventually derive and validate an improved version of the score (FLHASc2).

METHODS: We analyzed data from the POPEIHE study (NCT06067997), a multicenter prospective cohort of 546 consecutive adult patients presenting with hemoptysis to 9 Italian EDs. The primary outcome was a composite of in-hospital death, need for ventilatory support, intensive care unit (ICU) admission, blood transfusion, or invasive hemostatic procedures. We evaluated the prognostic performance of the original FLHASc, then derived a new model (FLHASc2) using multivariate logistic regression in a randomly selected derivation cohort (n = 321) and validated it in the remaining cohort (n = 225). A simplified version of the score was also tested.

RESULTS: The original FLHASc demonstrated moderate discriminatory ability (AUC 0.71; 95% CI: 0.65-0.76) and suboptimal calibration. The FLHASc2 showed improved performance (AUC 0.79, 95% CI: 0.73-0.87 in derivation and 0.81, 95% CI: 0.73-0.88, in validation cohorts; Brier score < 0.10 in both). The simplified FLHASc2 (sFLHASc2), assigning one point per variable, maintained comparable accuracy (AUC 0.80, 95% CI: 0.72-0.87) and identified 47.8% of patients as low risk (2.7% event rate). When combined with a negative chest X-ray, the observed event rate in this subgroup dropped to 0.87%, with a negative predictive value of 99.1% (CI 95%, 96.5-100%).

CONCLUSIONS: The FLHASc2 and its simplified version are accurate prognostic tools for identifying hemoptysis patients at low risk of short-term adverse outcomes. Use of the sFLHASc2 combined with chest X-ray may allow safe ED discharge in nearly half of cases. A prospective management trial is warranted to confirm its clinical impact.

TRIAL REGISTRATION NUMBER: NCT06067997.

来源:Am J Emerg Med,查看原文。版权归原作者所有。

参考来源

  1. Pelagatti L, Bartalucci P, Fabiani G, et al. Validation and implementation of the FLHASc score for risk stratification of patients with hemoptysis in the emergency department. Am J Emerg Med. 2026. PMID: 41905245. doi:10.1016/j.ajem.2026.03.020

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。